One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and ...

Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.

Scientists at The Wistar Institute have developed an HIV vaccine candidate that achieves something never before observed in ...

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists for four decades: it reliably produced potent, virus-blocking antibodies in ...

A supercharged HIV vaccine could offer strong protection with just one injection, a study in mice has indicated. Developed by researchers from the Massachusetts Institute of Technology (MIT) and the ...

The BRILLIANT 011 trial is testing two next-generation HIV vaccine components—BG505 GT1.1 and 426c.Mod.Core-C4b—administered ...

After decades of research, there is still no cure for the disease HIV causes–AIDS. Each year, HIV infects more than one million people worldwide, and a vaccine remains stubbornly out of reach. Hope, ...

Solving HIV vaccination—a puzzle that scientists have been tackling for decades without success—could be like cracking the code to a safe. The key, they now think, may be delivering a series of ...

Researchers at Massachusetts Institute of Technology (MIT) have developed a way to 'supercharge' vaccines to the extent that just a single dose can provide strong protection from HIV. Vaccines ...

HIV remains a major global public health challenge. Nowhere is this more evident than in southern and eastern Africa, where the majority of people living with HIV reside. Here new HIV infections ...

Please provide your email address to receive an email when new articles are posted on . Fifteen years ago, an HIV vaccine trial conducted in Thailand and sponsored by the U.S. Army found something no ...